A Phase II study of OSE-127 for Sjogren's syndrome
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2019
Price : $35 *
At a glance
- Drugs OSE 127 (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- 02 Dec 2019 According to an OSE Immunotherapeutics media release, the company expects to initiate this study in 2020.
- 26 Nov 2018 According to an OSE Immunotherapeutics media release, the company has signed a license option agreement with Servier in Dec 2016 for the development and commercialization of OSE-127, up to the completion of a phase 2 clinical trial, planned in ulcerative colitis (CT profile 280156) and in parallel in Sjogrens syndrome.
- 10 Apr 2018 New trial record